GlaxoSmithKline Plc Value Stock - Dividend - Research Selection
Market price: 13,55 GBP
GlaxoSmithKline Plc Fundamental data and company key figures of the share
|Annual reports in GBP|
|Net operating cash flow||7.647.000.000|
|Free cash flow||6.421.000.192|
|Liabilities & Shareholders equity||80.431.000.000|
|Diluted shares outstanding||5.038.000.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||89.670.565.888,00 USD|
|Raw Data Source||IFRS in Millionen GBP|
|Stock Split||2000-12-27,775.0000/1704.0000; 2000-12-26,775.0000/1704.0000; 1996-08-12,1030.0000/1013.0000; 1991-10-28,2.0000/1.0000; 1989-11-24,2.0000/1.0000|
Description of the company
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK's principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG.